What is Tumor Mutation Burden (TMB)?
- It is a genomic biomarker that quantifies the frequency of somatic(acquired over lifetime) mutations in a patient’s tumor
- A high TMB correlates with an aggressive tumor rapidly evolving with high incidence of somatic mutations in the tumor genome
Prevalence
As per GLOBOCAN 2020 report
- 19.3 Million people are affected by Cancer
- Global cancer burden is expected to reach 28.4 million cases in 2040 which signifies 40% increase in the next 20 years
Common Cancers
Lung Cancer
Breast Cancer
Ovarian Cancer
Prostate Cancer
Gastrointestinal Stromal Tumor
Thyroid Cancer
Colorectal Cancer
Melanoma
Bladder Cancer
Uterine Cancer
Pancreatic Cancer
Hepatocellular Carcinomas
Sarcomas
Thymus Cancer
Glioma
Why do you need the test?
- TMB is associated with improved response rate to immune checkpoint inhibitors
- It expands the population of patients who can be considered candidates for immunotherapy beyond standard PD-L1 testing
- FDA has approved Pembrolizumab for treating adult and pediatric patients with unresectable or metastatic solid tumors with high TMB (>10 Mut/Mb) that have progressed following previous therapy
Advantages of MedGenome’s Tumor Mutation Burden Test
- Provides quantification in terms of TMB score & accurate information on actionable mutations
- Single test that analyses all guideline-recommended genes in solid tumors
- Accurately identifies genomic alteration in >450 gene with therapeutic / prognostic relevance
- Covers 1.65 Mb genomic region, across >450 genes with median depth of coverage of 300X (LOD of 5% for SNVs and 10% for Indels)
- Panel is extensively validated using clinical specimens and standards
- Includes Unique Molecular Index based testing
Enquire
Now